AI blood tests for triple-negative breast cancer after treatment
Part of Cancer, Skin clinical trials.
This study uses a computer (AI) to read results from blood tests to look for signs of remaining triple-negative breast cancer, before and/or after surgery. It may help doctors better detect residual tumor and guide follow-up care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer is triple-negative (ER negative, PR negative, and HER2 negative)
- You are undergoing treatment where you receive at least 8 weeks of chemotherapy before surgery
- Your doctor believes there is still possible or confirmed tumor remaining (before surgery or after surgery pathology)
- You do not have evidence the cancer has spread to other organs (no metastatic disease)
- You can come for visits and provide blood samples regularly after surgery
- You can sign and understand the study consent, and you don’t have known HIV or hepatitis infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a way to use a simple blood test during chemotherapy to see how well the treatment is working in certain breast cancers. The goal is to make sure you get the best treatment for your tumor type.
This trial uses a simple blood test to look for leftover cancer DNA in people with triple-negative breast cancer who still have disease after chemotherapy and surgery. It aims to catch any early signs of the cancer coming back.
This trial tests whether using a blood test to detect leftover cancer DNA after initial treatment can help doctors decide if extra therapy is needed for people with early triple-negative breast cancer. It aims to improve outcomes for those with remaining disease after neoadjuvant therapy.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This study looks at the bacteria found in the tumor to see if they affect how well chemotherapy or immunotherapy works in treating triple-negative breast cancer. The goal is to find ways to predict treatment response and improve care.
This study is for people with early-stage triple-negative breast cancer (TNBC) that has not been treated yet. Researchers want to see if tracking tumor DNA in your blood can help guide treatment decisions. You would receive standard chemotherapy and surgery, plus give blood samples.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.